Maged Shenouda's Net Worth
$173 Thousand
Who is Maged Shenouda?
Maged Shenouda does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include RELMADA THERAPEUTICS, INC., AzurRx BioPharma, Inc., and Protea Biosciences Group, Inc..
SEC CIK
Maged Shenouda's CIK is 0001658369
Past Insider Trading and Trends
2021 was Maged Shenouda's most active year for acquiring shares with 11 total transactions. Maged Shenouda's most active month to acquire stocks was the month of November. 2021 was Maged Shenouda's most active year for disposing of shares, totalling 25 transactions. Maged Shenouda's most active month to dispose stocks was the month of January. 2019 saw Maged Shenouda paying a total of $6,338,894.00 for 620,978 shares, this is the most they've acquired in one year. In 2021 Maged Shenouda cashed out on 72,000 shares for a total of $1,257,011.72, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
RELMADA THERAPEUTICS, INC. (RLMD) Snapshot price: $5.5
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +1,466.56% | 32.67K |
$3.85 | $125,716.68 | 34.9K |
Jan 29 - Jan 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 17
| |||
Form 4
|
—
|
0
|
$19.35 | -$322,106.63 | 2.23K |
Scheduled
|
Mar 8 - Mar 10
| ||
Form 4
|
—
|
0
|
$18.71 | -$92,809.24 | 2.23K |
Scheduled
|
Feb 24
| ||
Form 4
|
—
|
0
|
$19.32 | -$45,915.34 | 2.23K |
Scheduled
|
Feb 11
| ||
Form 4
|
—
|
0
|
$19.21 | -$363,064.89 | 2.23K |
Scheduled
|
Feb 8 - Feb 10
| ||
Form 4
|
—
|
0
|
$19.14 | -$101,765.92 | 2.23K |
Scheduled
|
Feb 2 - Feb 3
| ||
Form 4
|
—
|
0
|
$17.59 | -$86,058.00 | 2.23K |
Scheduled
|
Jan 27
| ||
Form 4/A
| +179.53% | 4K |
$3.24 | $12,960.00 | 6.23K |
Jan 22
| |||
Form 4
|
—
|
0
|
$179.70 | $1,154,388.29 | 2.23K |
Scheduled
|
Jan 22 - Jan 26
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 19
| |||
Form 4
| +78.24% | 978 |
$23.00 | $22,494.00 | 2.23K |
Oct 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 20
| |||
Form 4
| +150.00% | 3K |
$2.99 | $8,957.59 | 5K |
Dec 15
| |||
Form 4
|
∞
| 2K |
$2.89 | $5,780.00 | 2K |
Dec 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
AzurRx BioPharma, Inc. (FWBI) Snapshot price: $5.22
CHIEF FINANCIAL OFFICER
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +47.06% | 20K |
$1.31 | $26,214.00 | 62.5K |
Dec 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 12
| |||
Form 4
| +112.50% | 22.5K |
—
|
—
| 42.5K |
Oct 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Protea Biosciences Group, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||